Medlab Clinical Ltd (ASX:MDC) CEO & managing director Dr. Sean Hall tells Proactive Investors, "probably one of the biggest things in medicine to date" is research into the human microbiome and its impact on human health.
Modern research on the field stems from The Human Microbiome Project conducted by the US National Institute of Health starting in 2008, intended to broaden medical understanding of the role of bacteria living in and on humans.
Medlab has taken particular interest in the gut microbiome, and its connection with various chronic diseases. Research into the link with depression is the most advanced, with human patients currently being recruited for Phase IIA clinical trials of NRGBiotic™. The biotech is also researching and developing probiotic applications for the treatment and management of diabetes and chronic kidney disease.